The estimated Net Worth of Jeffrey Bluestone is at least $571 Mille dollars as of 3 May 2022. Jeffrey Bluestone owns over 2,223 units of Provention Bio stock worth over $81,535 and over the last 6 years he sold PRVB stock worth over $87,089. In addition, he makes $402,177 as Director at Provention Bio.
Sign up
Jeffrey Bluestone PRVB stock SEC Form 4 insiders trading
Jeffrey has made over 4 trades of the Provention Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,223 units of PRVB stock worth $55,531 on 3 May 2022.
The largest trade he's ever made was exercising 32,246 units of Provention Bio stock on 10 April 2020 worth over $76,101. On average, Jeffrey trades about 3,058 units every 75 days since 2019. As of 3 May 2022 he still owns at least 3,264 units of Provention Bio stock.
You can see the complete history of Jeffrey Bluestone stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Bluestone biography
Dr. Jeffrey Bluestone Ph.D. serves as Director of the Company. Dr. Bluestone currently serves as the president and CEO of Sonoma Biotherapeutics. He also currently serves as the A.W. and Mary Margaret Clausen Distinguished Professor at University of California San Francisco (UCSF). He previously served as President and CEO of the Parker Institute for Cancer Immunotherapy from June 2015 to December 2019 and the director of the Hormone Research Institute in the Diabetes Center from 2000 to December 2019. From 2010 to 2015, Dr. Bluestone served as Executive Vice Chancellor and Provost at UCSF. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He was appointed by former Vice President, Joe Biden as a member of the Blue Ribbon Panel of scientific experts to guide the National Cancer Moonshot Initiative and also served as a senior investigator at the National Cancer Institute of the National Institutes of Health. Dr. Bluestone is a highly accomplished scientific researcher whose work over nearly three decades has focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved by the FDA for the treatment of metastatic melanoma. Dr. Bluestone was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes (T1D), psoriatic arthritis, and the reversal of kidney transplant rejection.
What is the salary of Jeffrey Bluestone?
As the Director of Provention Bio, the total compensation of Jeffrey Bluestone at Provention Bio is $402,177. There are 11 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
How old is Jeffrey Bluestone?
Jeffrey Bluestone is 67, he's been the Director of Provention Bio since 2019. There are 1 older and 16 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
What's Jeffrey Bluestone's mailing address?
Jeffrey's mailing address filed with the SEC is 333 LAKESIDE DRIVE, , FOSTER CITY, CA, 94404.
Insiders trading at Provention Bio
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski e Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
What does Provention Bio do?
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
What does Provention Bio's logo look like?
Complete history of Jeffrey Bluestone stock trades at Gilead Sciences e Provention Bio
Provention Bio executives and stock owners
Provention Bio executives and other stock owners filed with the SEC include:
-
Ashleigh Palmer,
President, Chief Executive Officer, Co-Founder, Director -
Eleanor Ramos,
Chief Medical Officer -
Francisco Leon,
Co-Founder, Chief Scientific Officer -
Andrew Drechsler,
Chief Financial Officer -
Ashleigh W. Palmer B.Sc., M.B.A.,
Co-Founder, Pres, CEO & Director -
Sean Doherty,
Independent Director -
Dr. Eleanor L. Ramos,
Chief Medical Officer -
Dr. Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jason Hoitt,
Chief Commercial Officer -
Andrew T. Drechsler,
Special Advisor -
Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jeffrey Bluestone,
Director -
Wayne Pisano,
Independent Chairman of the Board -
Avery Catlin,
Independent Director -
Sam Martin,
Investor Relations -
Nancy Wysenski,
Director -
John Jenkins,
Director -
Heidy King-Jones,
Chief Legal Officer -
Jason Hoitt,
Chief Commercial Officer -
Robert A. Doody Jr.,
VP of Investor Relations -
Christina Yi,
Chief Operations Officer -
Thierry Chauche,
Chief Financial Officer -
Dr. Sherron Kell,
Sr. VP of Clinical Devel. -
Heidy Abreu King-Jones J.D., L.L.M.,
Chief Legal Officer -
Justin Vogel,
Chief Accounting Officer -
Anthony Digiandomenico,
Director -
Miyoko Christina Yi,
Chief Operations Officer -
Benedict Osorio,
Chief Quality Officer -
Thierry Chauche,
Chief Financial Officer -
Rita Jain,
Director -
Sarah O'brien,
Chief People Officer -
Capital (Master), L.P.Sessa...,